---
title: "LCatlas: Point-of-Care Prediction Tool for Immunotherapy Response in NSCLC"
id: "medrxiv-19-lcatlas-a-point-of-care-tool-for-predicting-immunotherapy-outcomes-in-non-small"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-19-lcatlas-a-point-of-care-tool-for-predicting-immunotherapy-outcomes-in-non-small"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.11.18.26368446v1?rss=1"
published_at: "2026-11-20T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# LCatlas: Point-of-Care Prediction Tool for Immunotherapy Response in NSCLC
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-19-lcatlas-a-point-of-care-tool-for-predicting-immunotherapy-outcomes-in-non-small
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.11.18.26368446v1?rss=1)
- **Published At:** 2026-11-20T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Investigators developed **LCatlas**, a web-based point-of-care application accessible at https://www.lcatlas.org, designed to predict response to first-line **immunotherapy** in **non-small cell lung cancer** (NSCLC). - The study team extracted demographic, clinical, and molecular features from electronic medical records for a development cohort of 79 NSCLC patients treated with first-line immune checkpoint inhibitors. - Model inputs accepted by LCatlas are nine variables: gender, smoking history, bone/pleura/liver metastasis, **PDL1** tumor staining, albumin, hemoglobin, lymphocyte, neutrophil, and platelet counts. - Investigators compared three approaches: logistic regression (statistical), XGBoost (machine learning), and TabTransformer (AI). The best-performing model was used for the web application. - Cross-validation performance reported an AUC of 79% (72%–85%), sensitivity 87% (72%–95%), and specificity 78% (64%–89%), according to the authors. - A separate validation cohort of 28 individuals yielded a reported prediction accuracy of 82% for the tool. - The authors reported that LCatlas predicted response to both single-agent immunotherapy and immunotherapy combined with chemotherapy. - The preprint notes institutional IRB approval (University of Southern California IRB HS-15-00200) and a waiver of informed consent due to the retrospective design. - Authors declared competing interests for some coauthors; other authors reported no conflicts. The article is a medRxiv preprint and has not undergone peer review. - Data and the application are publicly available; the source did not report additional prospective validation, external multicenter testing, or detailed model hyperparameters in the abstract.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=jZaCyktpaDuUbI_xSDvEv04LLF4PhUNck2Ng4LByBcI-1795203151.823841-1.2.1.1-hifeTCZCBdoeBM_m8DcTbGuO6Ql1EuCv_GGVin7nT8HaBtudCFxhrnCaA2.wvtTs) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.11.18.26368446v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # LCatlas: A Point-Of-Care Tool for Predicting Immunotherapy Outcomes in Non-Small Cell Lung Cancer Sung Yong Park, Alexis Leyba, Wilson Yeung, Robert C Hsu, Jorge Nieva, Ha Youn Lee doi: https://doi.org/10.64898/2026.11.18.26368446 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Sung Yong Park 1 Keck School of Medicine, USC; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Sung%2BYong%2BPark%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Park%20SY&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ASung%2BYong%2BPark%2B) Alexis Leyba 2 University of Southern California Norris Comprehensive Cancer Center * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Alexis%2BLeyba%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Leyba%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAlexis%2BLeyba%2B) Wilson Yeung 2 University of Southern California Norris Comprehensive Cancer Center * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Wilson%2BYeung%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Yeung%20W&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AWilson%2BYeung%2B) Robert C Hsu 2 University of Southern California Norris Comprehensive Cancer Center * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Robert%2BC%2BHsu%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Hsu%20RC&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ARobert%2BC%2BHsu%2B) Jorge Nieva 2 University of Southern California Norris Comprehensive Cancer Center * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Jorge%2BNieva%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Nieva%20J&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJorge%2BNieva%2B) Ha Youn Lee 1 Keck School of Medicine, USC; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Ha%2BYoun%2BLee%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Lee%20HY&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AHa%2BYoun%2BLee%2B) * For correspondence: hayoun@usc.edu * [Abstract](https://www.medrxiv.org/content/10.64898/2026.11.18.26368446v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1349796/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.11.18.26368446v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1349796/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.11.18.26368446v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1349796/1) * [Supplementary material](https://www.medrxiv.org/content/10.64898/2026.11.18.26368446v1.supplementary-material)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_data/node:1349796/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.11.18.26368446v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1349796/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.11.18.26368446v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1349796/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Non-small cell lung cancer (NSCLC) remains a leading cause of cancer mortality, with a minority of patients experiencing durable responses to first-line immune checkpoint inhibitors (ICIs). Currently, there are no easily accessible tools to predict clinical benefit to first-line immunotherapy. To address this gap, we developed LCatlas (https://www.lcatlas.org), a point-of-care web application designed to predict immunotherapy outcomes and inform evidence-based treatment decisions. Using data from 79 NSCLC patients receiving first-line immunotherapy, we extracted demographic, clinical, and molecular features from electronic medical records and compared three independent approaches, statistical model (logistic regression), machine learning (XGboost), and AI model (TabTransformer) to identify the most effective predictor. LCatlas accepts nine variables, gender, smoking history, bone/pleura/liver metastasis, PDL1 tumor staining, albumin level, hemoglobin level, lymphocyte count, neutrophil count, and platelet count, to predict responses to both immunotherapy and immunotherapy plus chemotherapy. LCatlas cross-validation yielded an area under the curve (AUC) of 79% [72% - 85%], with sensitivity of 87% [72% - 95%] and specificity of 78% [64% - 89%], outperforming previous studies including high-volume data-driven deep-learning approaches. In a validation cohort consisting of 28 individuals, it demonstrated a prediction accuracy of 82%. LCatlas may serve as a valuable point-of-care tool by identifying patients likely to experience extended immunotherapy or combination therapy using readily available medical data. Its evidence-based approach can optimize personalized treatment planning and thereby promote quality and safety of care. ### Competing Interest Statement RH is a consultant for EMD Serono, Boehringer Ingelheim, Johnson & Johnson, Caris, Oncohost, MJH Life Sciences, Takeda, Regeneron, AstraZeneca, Jazz Pharmaceuticals. Receives honoraria from DAVA Oncology, The Dedham Group. Research funding to institution from Bristol Myers Squibb Foundation. JN receives consulting fees from Aadi Biosciences, ANP Technologies, Astra Zeneca, BioAtla, BMS, Catalym, Gilead, Genentech, Kalivir, Pfizer, Sanofi, Tubulis, and Urogen; research support from Genentech and Merck; intellectual property licensing fees from Cansera; has ownership interests in Affyimmune, Cansera, Epic Sciences, Indee Bio, Quantgene, Amgen, Johnson & Johnson, and Novartis. All other authors declare no conflicts of interests. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Access to patient records was approved by the University of Southern California Institutional Review Board (IRB HS-15-00200). Given the retrospective nature of the study, informed consent was waived. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability LCatlas is publicly available at https://www.lcatlas.org. Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.11.18.26368446v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.11.18.26368409v1 "Improving UK Biobank algorithms for Parkinson's disease ascertainment using drug claims")[Next ](https://www.medrxiv.org/content/10.64898/2026.11.18.26368397v1 "Detection of Peanut Allergy Sensitization and Monitoring of Type 2 Memory B cells Using Recombinant Peanut Allergen Components") Posted November 20, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.11.18.26368446v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/11/20/2026.11.18.26368446.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.11.18.26368446v1#p-5) [Supplementary Material ](https://www.medrxiv.org/content/10.64898/2026.11.18.26368446v1.supplementary-material) [ Data/Code](https://www.medrxiv.org/content/early/2026/11/20/2026.11.18.26368446.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) LCatlas: A Point-Of-Care Tool for Predicting Immunotherapy Outcomes in Non-Small Cell Lung Cancer Sung Yong Park, Alexis Leyba, Wilson Yeung, Robert C Hsu, Jorge Nieva, Ha Youn Lee medRxiv 2026.11.18.26368446; doi: https://doi.org/10.64898/2026.11.18.26368446 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.18.26368446v1%26text%3DLCatlas%253A%2520A%2520Point-Of-Care%2520Tool%2520for%2520Predicting%2520Immunotherapy%2520Outcomes%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.18.26368446v1%26t%3DLCatlas%253A%2520A%2520Point-Of-Care%2520Tool%2520for%2520Predicting%2520Immunotherapy%2520Outcomes%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.18.26368446v1%26title%3DLCatlas%253A%2520A%2520Point-Of-Care%2520Tool%2520for%2520Predicting%2520Immunotherapy%2520Outcomes%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.18.26368446v1%26title%3DLCatlas%253A%2520A%2520Point-Of-Care%2520Tool%2520for%2520Predicting%2520Immunotherapy%2520Outcomes%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.11.18.26368446) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.64898/2026.11.18.26368446v1&count=horizontal&via=&text=LCatlas%3A%20A%20Point-Of-Care%20Tool%20for%20Predicting%20Immunotherapy%20Outcomes%20in%20Non-Small%20Cell%20Lung%20Cancer&counturl=www.medrxiv.org/content/10.64898/2026.11.18.26368446v1 "Tweet This") ## Subject Area * [Oncology ](https://www.medrxiv.org/collection/oncology) Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (642) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (927) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (355) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (5055) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (496) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (432) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (681) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1703) * [Epidemiology](https://www.medrxiv.org/collection/epidemiology) (16343) * [Forensic Medicine](https://www.medrxiv.org/collection/forensic-medicine) (37) * [Gastroenterology](https://www.medrxiv.org/collection/gastroenterology) (1248) * [Genetic and Genomic Medicine](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) (7330) * [Geriatric Medicine](https://www.medrxiv.org/collection/geriatric-medicine) (760) * [Health Economics](https://www.medrxiv.org/collection/health-economics) (1101) * [Health Informatics](https://www.medrxiv.org/collection/health-informatics) (5348) * [Health Policy](https://www.medrxiv.org/collection/health-policy) (1480) * [Health Systems and Quality Improvement](https://www.medrxiv.org/collection/health-systems-and-quality-improvement) (1847) * [Hematology](https://www.medrxiv.org/collection/hematology) (604) * [HIV/AIDS](https://www.medrxiv.org/collection/hiv-aids) (1389) * [Infectious Diseases (except HIV/AIDS)](https://www.medrxiv.org/collection/infectious_diseases) (16535) * [Intensive Care and Critical Care Medicine](https://www.medrxiv.org/collection/intensive-care-and-critical-care-medicine) (1209) * [Medical Education](https://www.medrxiv.org/collection/medical-education) (702) * [Medical Ethics](https://www.medrxiv.org/collection/medical-ethics) (157) * [Nephrology](https://www.medrxiv.org/collection/nephrology) (757) * [Neurology](https://www.medrxiv.org/collection/neurology) (7659) * [Nursing](https://www.medrxiv.org/collection/nursing) (380) * [Nutrition](https://www.medrxiv.org/collection/nutrition) (1143) * [Obstetrics and Gynecology](https://www.medrxiv.org/collection/obstetrics-and-gynecology) (1306) * [Occupational and Environmental Health](https://www.medrxiv.org/collection/occupational-and-environmental-health) (1045) * [Oncology](https://www.medrxiv.org/collection/oncology) (3766) * [Ophthalmology](https://www.medrxiv.org/collection/ophthalmology) (1105) * [Orthopedics](https://www.medrxiv.org/collection/orthopedics) (413) * [Otolaryngology](https://www.medrxiv.org/collection/otolaryngology) (473) * [Pain Medicine](https://www.medrxiv.org/collection/pain-medicine) (506) * [Palliative Medicine](https://www.medrxiv.org/collection/palliative-medicine) (144) * [Pathology](https://www.medrxiv.org/collection/pathology) (726) * [Pediatrics](https://www.medrxiv.org/collection/pediatrics) (1877) * [Pharmacology and Therapeutics](https://www.medrxiv.org/collection/pharmacology-and-therapeutics) (758) * [Primary Care Research](https://www.medrxiv.org/collection/primary-care-research) (791) * [Psychiatry and Clinical Psychology](https://www.medrxiv.org/collection/psychiatry-and-clinical-psychology) (6184) * [Public and Global Health](https://www.medrxiv.org/collection/public-and-global-health) (10050) * [Radiology and Imaging](https://www.medrxiv.org/collection/radiology-and-imaging) (2560) * [Rehabilitation Medicine and Physical Therapy](https://www.medrxiv.org/collection/rehabilitation-medicine-and-physical-therapy) (1539) * [Respiratory Medicine](https://www.medrxiv.org/collection/respiratory-medicine) (1280) * [Rheumatology](https://www.medrxiv.org/collection/rheumatology) (666) * [Sexual and Reproductive Health](https://www.medrxiv.org/collection/sexual-and-reproductive-health) (814) * [Sports Medicine](https://www.medrxiv.org/collection/sports-medicine) (601) * [Surgery](https://www.medrxiv.org/collection/surgery) (809) * [Toxicology](https://www.medrxiv.org/collection/toxicology) (109) * [Transplantation](https://www.medrxiv.org/collection/transplantation) (321) * [Urology](https://www.medrxiv.org/collection/urology) (309) Evaluation/discussion of this paper x Comments 0TRiP 0Community 0Automated 0Blogs/Media 0Video 0 Comments medRxiv aims to provide a venue for anyone to comment on a medRxiv preprint. Comments are moderated for offensive or irrelevant content (this can take ~24 h). Please avoid duplicate submissions. The content of a comment is not endorsed by medRxiv. medRxiv is now using a new commenting interface powered by Hypothes.is. All comments previously submitted via the legacy platform (Disqus) have been transferre
## Related Clinical Research

- [Pope Leo XIV Diagnosed with Lung Adenocarcinoma: Key Insights](https://medichelpline.com/clinical-feed/medical-news-today-0-pope-leo-lung-cancer-diagnosis-what-to-know-about-lung-adenocarcinoma.md)
- [Rare genetic variant linked to 25-fold higher lung cancer risk in never-smokers](https://medichelpline.com/clinical-feed/stat-news-0-stat-why-do-never-smokers-get-lung-cancer-in-some-cases-rare-genetic-variant.md)
- [Daraxonrasib shows activity in RAS‑mutant NSCLC after FDA approval in pancreatic cancer](https://medichelpline.com/clinical-feed/medical-news-today-0-pancreatic-cancer-drug-may-also-help-fight-treatment-resistant-lung-cancer.md)
- [Bupropion Hydrochloride for Improving Recovery in Acute Ischaemic Stroke: BASE Trial Protocol](https://medichelpline.com/clinical-feed/bmj-open-4-protocol-for-base-a-multicentre-double-blind-randomised-controlled-trial-of.md)
- [Early STAT+ Results for Alterome’s KRAS Inhibitor in Pancreatic, Lung, and Colorectal Cancer](https://medichelpline.com/clinical-feed/stat-news-1-stat-early-results-for-alterome-s-kras-drug-for-pancreas-lung-and-colon-cancer.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.